Abstract
In March 2020 the WHO declared that COVID-19 had reached pandemic state. To date the primary focus internationally has been on the preservation of life. For those with pre-existing neurological disease, there is an additional concern with early evidence suggesting this group could be predisposed to adverse outcomes. Multiple sclerosis (MS) patients are a particularly vulnerable group during this pandemic. The combination of an autoimmune neurodegenerative disorder and the immunosuppression caused by the typically prescribed pharmacological agents augments the risk of complications in this group [1]. As a public health precaution, international governmental bodies recommended that people with multiple sclerosis (pwMS) self-isolate as much as possible to reduce their risk of contracting the virus.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
